Compugen (CGEN) Lifted to “Hold” at ValuEngine
ValuEngine upgraded shares of Compugen (NASDAQ:CGEN) from a sell rating to a hold rating in a research report sent to investors on Thursday.
Separately, Zacks Investment Research lowered shares of Compugen from a buy rating to a hold rating in a report on Monday, January 22nd.
Shares of Compugen (NASDAQ CGEN) opened at $3.80 on Thursday. The firm has a market cap of $195.49, a PE ratio of -5.28 and a beta of 0.30. Compugen has a 1-year low of $2.25 and a 1-year high of $5.40.
Hedge funds have recently added to or reduced their stakes in the stock. Paloma Partners Management Co bought a new position in Compugen in the fourth quarter worth about $105,000. Virtu Financial LLC bought a new position in Compugen in the fourth quarter worth about $162,000. Jane Street Group LLC bought a new position in Compugen in the fourth quarter worth about $192,000. Benjamin F. Edwards & Company Inc. raised its stake in Compugen by 35.4% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 85,300 shares of the biotechnology company’s stock worth $213,000 after buying an additional 22,305 shares in the last quarter. Finally, Anson Funds Management LP bought a new position in Compugen in the fourth quarter worth about $281,000. 23.49% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Compugen (CGEN) Lifted to “Hold” at ValuEngine” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.watchlistnews.com/compugen-cgen-lifted-to-hold-at-valuengine/1909759.html.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.